PET and MRI Imaging of Brain Tumors Using [18F]PARPi

Sponsor

Memorial Sloan Kettering Cancer Center (Other)

Overall Status

Recruiting

CT.gov ID

NCT04173104

Collaborator

(none)

Enrollment

Location

Anticipated Duration (Months)

0.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study is to collect data about how 18FPARPi can be used together with PET/positron emission tomography and MRI/magnetic resonance imaging scans to take pictures of brain cancer

Condition or Disease	Intervention/Treatment	Phase
Brain Tumor Brain Cancer	Diagnostic Test: PET/MR with [18F]PARPi Drug: [18F]PARPi

Study Design

Study Type:

Observational

Anticipated Enrollment :

8 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Official Title:

Pilot Study of [18F]PARPi PET/MR Imaging in Patients With New and/or Suspected Recurrent Brain Tumors

Actual Study Start Date :

Nov 1, 2019

Anticipated Primary Completion Date :

Nov 1, 2023

Anticipated Study Completion Date :

Nov 1, 2023

Arms and Interventions

Arm	Intervention/Treatment
Participants with Brain Cancer Participants with new or suspected recurrent brain tumors	Diagnostic Test: PET/MR with [18F]PARPi One PET/MR study (with up to 3 scan times) with [18F]PARPi Drug: [18F]PARPi Injection of <100ug of [18F]PARPi prior to 1 PET/MR

Arm

Intervention/Treatment

Participants with Brain Cancer

Participants with new or suspected recurrent brain tumors

Diagnostic Test: PET/MR with [18F]PARPi

One PET/MR study (with up to 3 scan times) with [18F]PARPi

Drug: [18F]PARPi

Injection of <100ug of [18F]PARPi prior to 1 PET/MR

Outcome Measures

Primary Outcome Measures

SUVmax measurements [Up to 24 weeks]
[18F]PARPi updtake in lesions will be quantified by standard SUVmax measurements from PET/MR scans

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patients with new or suspected recurrent brain tumors (including suspected recurrent brain tumors showing growth from any preceding scan)
Age >/= 18 years
Minimum at least one brain lesion size >/= 1.5cm diameter
Scheduled to undergo treatment at MSK
Willingness to sign informed consent
Able to receive intravenous gadolinium contrast per MSK Department of Radiology guidelines